Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. (MIST) is a clinical-stage biopharmaceutical company pioneering patient-administered therapies for cardiovascular emergencies. This page serves as the definitive source for verified news and press releases related to MIST's innovative arrhythmia treatments, including etripamil nasal spray for PSVT and AFib-RVR management.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection provides essential insights into the company's scientific advancements while maintaining compliance with financial disclosure standards.
Key content categories include FDA submission updates, phase 3 trial results analysis, intellectual property developments, and executive leadership announcements. All materials are vetted for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to MIST's latest developments in rapid-onset cardiovascular therapies. Check regularly for updates on groundbreaking treatment models that combine medical innovation with patient empowerment.
On February 28, 2023, Milestone Pharmaceuticals (Nasdaq: MIST) announced its management team will present at two upcoming investor conferences. The events include the Cowen 43rd Annual Health Care Conference on March 7 at 1:30 p.m. ET and the Oppenheimer 33rd Annual Healthcare Conference on March 14 at 2:40 p.m. ET. Live webcasts of the presentations can be accessed on Milestone's website, with archived replays available for approximately 90 days. Milestone focuses on cardiovascular medicines, with its lead candidate, etripamil, having completed Phase 3 trials for paroxysmal supraventricular tachycardia and a Phase 2 trial for atrial fibrillation.
Milestone Pharmaceuticals (Nasdaq: MIST) will host a virtual deep-dive event on December 6, 2022 at 1:00 p.m. ET to discuss the commercial prospects of etripamil, its lead investigational product for treating paroxysmal supraventricular tachycardia (PSVT). This condition affects around two million Americans and is characterized by sudden episodes of rapid heartbeat. Etripamil is a self-administered nasal spray aimed at improving treatment accessibility, shifting care from emergency settings. For more information, visit Milestone's website.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical firm dedicated to cardiovascular medicine, announced management participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:30 p.m. ET in New York, NY. Investors can access a live webcast via Milestone's website, with an archived replay available for 90 days post-event. Milestone's lead product, etripamil, is in Phase 3 trials for treating paroxysmal supraventricular tachycardia and Phase 2 for atrial fibrillation with rapid ventricular rate.
Milestone Pharmaceuticals reported significant progress with its lead product, etripamil, in treating paroxysmal supraventricular tachycardia (PSVT). The Phase 3 RAPID trial achieved its primary efficacy endpoint with 64.3% of patients converting to sinus rhythm compared to 31.2% on placebo. Safety data remains consistent with previous studies. The company plans to submit a New Drug Application to the FDA in mid-2023. Financially, Milestone had $77.2 million in cash and reported an operating loss of $14.6 million for Q3 2022, slightly higher than the prior year.
Milestone Pharmaceuticals (MIST) reported positive results from its Phase 3 RAPID trial of etripamil, a nasal spray for paroxysmal supraventricular tachycardia (PSVT). The trial achieved its primary endpoint, with 64.3% of etripamil patients converting to sinus rhythm within 30 minutes compared to 31.2% with placebo (HR = 2.62, p<0.001). Median conversion time was 17 minutes for etripamil users. Additionally, fewer medical interventions and emergency visits were noted. Safety data supported its self-administration potential. Milestone plans to submit a New Drug Application for etripamil in mid-2023.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced a late-breaking presentation of data from the Phase 3 RAPID clinical trial focusing on etripamil for paroxysmal supraventricular tachycardia (PSVT). This presentation will occur at the American Heart Association Scientific Sessions 2022 from November 5-7, 2022. The trial data highlights etripamil's potential as a self-administered treatment, aiming to enhance patient convenience by shifting care from emergency settings to home use.
Milestone Pharmaceuticals (Nasdaq: MIST) announced successful results from the Phase 3 RAPID trial of etripamil, a nasal spray for treating paroxysmal supraventricular tachycardia (PSVT). The trial achieved its primary endpoint, with 64.3% of patients converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001). Safety data indicated tolerability, with no serious adverse events reported. Milestone plans to file a New Drug Application (NDA) with the U.S. FDA in mid-2023, further supporting the potential for etripamil as a self-administered treatment.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 12:00 p.m. ET in New York, NY. The presentation will be accessible via live webcast on Milestone's website, with an archived replay available for 90 days. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate etripamil in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation. For more details, visit www.milestonepharma.com.
Milestone Pharmaceuticals Inc. (MIST) reported substantial progress in its Phase 3 PSVT clinical program, achieving the required 180 confirmed events for the RAPID study. The topline data readout is expected in mid-second half of 2022. Financially, the company had $86.2 million in cash as of June 30, 2022, but incurred operating losses of $16.8 million for Q2, marking a significant decline from a prior year income of $0.7 million. Research and development expenses rose to $10.7 million due to advancing clinical trials, while general and administrative costs increased to $3.9 million.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 PM ET in New York, NY. Joseph Oliveto, the President and CEO, will lead the discussion. A live webcast will be accessible in the News & Events section of Milestone's website, with an archived replay available for 90 days post-event. Milestone focuses on innovative cardiovascular medicines, with its lead candidate etripamil in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation.
FAQ
What is the current stock price of Milestone Pharmaceuticals (MIST)?
What is the market cap of Milestone Pharmaceuticals (MIST)?
